6-(2-aminopyrimidin-5-yl)-8-chloro-10-methyl-3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one;8-chloro-6-(2-methoxypyrimidin-5-yl)-10-methyl-3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one;8-fluoro-10-methyl-6-pyrimidin-5-yl-3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(2-aminopyrimidin-5-yl)-8-chloro-10-methyl-3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one;8-chloro-6-(2-methoxypyrimidin-5-yl)-10-methyl-3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one;8-fluoro-10-methyl-6-pyrimidin-5-yl-3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one
• 化学式: C49H42Cl2FN13O4
• 分子量: 966.8
• InChiKey: QAWCCKIRNJVQDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.49
• 重原子数：
  69
• 可旋转键数：
  4
• 环数：
  12.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  215
• 氢给体数：
  4
• 氢受体数：
  12

文献信息

• [EN] PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE<br/>[FR] PIPÉRAZINO[1,2-A]INDOL-1-ONES ET [1,4]DIAZÉPINO[1,2-A]INDOL-1-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014023674A1

  公开（公告）日：2014-02-13

  The present invention relates to compounds of general formula (I), wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkoxy substituted by halogen or cyano; R2 is hydrogen, lower alkyl or lower alkyl substituted by halogen; R3 is phenyl, benzo[1,3]dioxolyl, 2,3-dihydro-benzofuran-5-yl or a 5- and 6-membered heteroaryl, wherein phenyl and the 5- and 6-membered heteroaryl groups may be substituted by one or more substituents, selected from cyano, nitro, amino and lower di-alkylamino, lower alkyl sulfonyl, lower alkoxy, lower alkoxy substituted by halogen, halogen, lower alkyl, lower alkyl substituted by halogen or lower alkyl substituted by hydroxyl; X is -CH(lower alkyl)-, -CH2-, -CH2CH2- or –CH(lower alkyl)CH2-; R is hydrogen or lower alkyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及一般式（I）的化合物，其中R1是氢、卤素、较低烷基、较低烷氧基、被卤素或氰基取代的较低烷氧基；R2是氢、较低烷基或被卤素取代的较低烷基；R3是苯基、苯并[1,3]二噁英基、2,3-二氢-苯并呋喃-5-基或5-和6-成员杂芳基，其中苯基和5-和6-成员杂芳基可能被氰基、硝基、氨基和较低二烷基氨基、较低烷基磺酰基、较低烷氧基、被卤素取代的较低烷氧基、卤素、较低烷基、被卤素取代的较低烷基或被羟基取代的较低烷基等一个或多个取代基取代；X是-CH（较低烷基）-、-CH2-、-CH2CH2-或-CH（较低烷基）CH2-；R是氢或较低烷基；n是1或2；或是药学上可接受的酸盐，或是外消旋混合物，或是其对映体和/或光学异构体。这些化合物可用于治疗精神分裂症、强迫性人格障碍、重度抑郁症、躁郁症、焦虑障碍、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍、唐氏综合征、自闭症谱系障碍、听力丧失、耳鸣、脊髓小脑共济失调、肌萎缩性侧索硬化、多发性硬化、亨廷顿病、中风、放射治疗、慢性压力、对神经活性药物的滥用，如酒精、阿片类药物、甲基苯丙胺、芬西克林和可卡因。
• PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2880036A1

  公开（公告）日：2015-06-10